Anti-hypertensive effect of Gastrodia elata Bl leaf extract in rats
Purpose: To investigate the probable antihypertensive effects of Gastrodia elata Bl. extract (GEBE) in renovascular hypertensive rats as well as the mechanism involved in blood pressure reduction.
Methods: The two-kidney one-clip (2K1C) Goldblatt model of renovascular hypertension was used in Wistar rats. The 2K1C group rats were treated with captopril (40 mg/kg/day), low-dose GEBE (150 mg/kg/day) and high-dose of GEBE (300 mg/kg/day) for 6 weeks by intragastric administration. Systolic (SBP) and diastolic blood pressure (DBP) were measured by the tail-cuff method. Urine creatinine and urea levels of the rats were measured by enzyme-linked immunosorbent assay (ELISA). Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were also evaluated.
Results: In the captopril- and GEBE-treated groups, blood pressure decreased progressively over the course of the 6-week treatment period compared with that of the untreated (control) rats (p < 0.01). High-dose GEBE also significantly increased plasma SOD activity but decreased plasma MDA concentration (p < 0.05). Renal function improved following captopril and GEBE (300 mg/kg/day) treatment (p < 0.01).
Conclusion: The results suggest that GEBE probably exerts an antihypertensive effect by inhibiting endothelin (ET)-converting enzyme and via its antioxidant activity.
Keywords: Antihypertensive, Gastrodia elata, Goldblatt renovascular hypertension, Endothelin-1, Hypertrophy
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.